Medpace (MEDP)

• Market cap: $8.35B
• 1 day: 0.67%
• 5 days: 5.90%
• 1 month: 1.21%
• 3 months: -11.90%
• 6 months: -3.13%
• Year to date: -7.87%
• 1 year: -20.59%
• 5 years: 286.16%
• 10 years: 1,009.72%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Employees: 5,900

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

14% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 81

12% more call options, than puts

Call options by funds: $26.1M | Put options by funds: $23.4M

4% more repeat investments, than reductions

Existing positions increased: 214 | Existing positions reduced: 206

0% more capital invested

Capital invested by funds: $8.38B [Q3] → $8.4B (+$26.7M) [Q4]

0.31% more ownership

Funds ownership: 81.06% [Q3] → 81.38% (+0.31%) [Q4]

0% more funds holding

Funds holding: 577 [Q3] → 578 (+1) [Q4]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 6 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $300 3% downside
• Avg. target: $325 5% upside
• High target: $355 15% upside

5 analyst ratings

• positive: 1 20%
• neutral: 4 80%
• negative: 0 0%

Truist Securities Jailendra Singh 34% 1-year accuracy 12 / 35 met price target	3% downside $300	Hold Maintained	23 Apr 2025
Baird Eric Coldwell 45% 1-year accuracy 14 / 31 met price target	1% upside $313	Neutral Maintained	23 Apr 2025
TD Cowen Charles Rhyee 13% 1-year accuracy 1 / 8 met price target	6% upside $328	Hold Downgraded	14 Apr 2025
Mizuho Ann Hynes 57% 1-year accuracy 12 / 21 met price target	15% upside $355	Outperform Maintained	9 Apr 2025
Leerink Partners Michael Cherny 71% 1-year accuracy 20 / 28 met price target	7% upside $330	Market Perform Initiated	24 Mar 2025